Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
出版年份 2021 全文链接
标题
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
作者
关键词
-
出版物
Metabolites
Volume 11, Issue 2, Pages 73
出版商
MDPI AG
发表日期
2021-01-27
DOI
10.3390/metabo11020073
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
- (2020) Kenneth Cusi LIVER INTERNATIONAL
- Complications, morbidity and mortality of nonalcoholic fatty liver disease
- (2020) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity
- (2020) Amedeo Lonardo et al. Annals of Hepatology
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
- (2020) Amedeo Lonardo et al. Journal of Clinical Medicine
- Contributions of amino acid, acylcarnitine and sphingolipid profiles to type 2 diabetes risk among South-Asian Surinamese and Dutch adults
- (2020) Mirthe Muilwijk et al. BMJ Open Diabetes Research & Care
- Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD
- (2020) Giovanni Targher ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
- (2020) Jiahua Li et al. Clinical Journal of the American Society of Nephrology
- Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
- (2020) Jeffrey Budd et al. Current Diabetes Reports
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
- (2020) Alessandro Mantovani et al. GUT
- Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
- (2020) Alexandros Sachinidis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis
- (2020) Simona Panunzi et al. DIABETES OBESITY & METABOLISM
- Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
- (2020) Maria-Styliani Kalogirou et al. Clinics and Research in Hepatology and Gastroenterology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Sex Differences in NAFLD : State of the Art and Identification of Research Gaps
- (2019) Amedeo Lonardo et al. HEPATOLOGY
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation
- (2019) Maurice B. Bizino et al. DIABETOLOGIA
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
- (2018) Frédéric Brioude et al. Nature Reviews Endocrinology
- Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults
- (2018) Christopher D Byrne et al. BMJ-British Medical Journal
- Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults
- (2018) Christopher D Byrne et al. BMJ-British Medical Journal
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option
- (2017) Gauri Dhir et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
- (2016) Timothy Hardy et al. Annual Review of Pathology-Mechanisms of Disease
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease
- (2015) Ilkay S Idilman et al. ACTA RADIOLOGICA
- Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies
- (2015) Wenjuan Tang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
- (2015) Amedeo Lonardo et al. DIGESTIVE AND LIVER DISEASE
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
- (2014) Nanda Gruben et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
- (2013) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Serum Levels of Acylcarnitines Are Altered in Prediabetic Conditions
- (2013) Manuel Mai et al. PLoS One
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
- (2012) James L. Trevaskis et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans
- (2012) Susan Cheng et al. CIRCULATION
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now